Similarly, another study using the fatty-acid hydrolase inhibitor URB597 combined with paclitaxel against mammary and ovarian tumor cells demonstrated that HSA produced higher synergy values compared to Bliss or Loewe models [22]. Here, ALB is linked to ovarian neoplasm.